Abstract
BACKGROUND: Urinary tract infections (UTIs) are among the most common infections encountered globally. Diagnosis often relies on symptoms, pyuria, and urine cultures. However, traditional methods like urine culture are time-consuming and lack immediate applicability. This study evaluates the role of urinary IL-6 as a diagnostic and prognostic biomarker, exploring its potential to guide treatment and augment antimicrobial stewardship practices. [Figure: see text] [Figure: see text] METHODS: This hospital-based observational study enrolled 88 patients aged >15 years with culture-positive UTIs. Urinary IL-6 levels were assessed before and 72 hours after antibiotic initiation. IL-6 was analysed using the Roche Elecsys® e801 automated immunoassay analyser. Clinical data, including symptoms, laboratory markers (WBC counts, urine pus cells, urine culture), and antibiotic use, were recorded. Data were analysed using SPSS v28. IL-6 cutoffs were evaluated using receiver operating characteristic (ROC) curves. Statistical significance was set at p < 0.05. [Figure: see text] [Figure: see text] RESULTS: The study population had an average age of 50.26 years, with a female predominance (62.5%). The most common symptom was fever (87.5%), followed by dysuria (73.9%). E. coli was the leading pathogen (50%), followed by Klebsiella and Enterococcus (17% each) (Fig 1). Piperacillin-tazobactam was the most frequently prescribed antibiotic. Mean antibiotic duration was 9.35 days. Urinary IL-6 levels on Day 0 were significantly elevated in UTI cases (mean 223.46 pg/mL), and decreased significantly after 72 hours of antibiotic therapy (mean 24.57 pg/mL) (p< 0.001) (Fig 2). IL-6 levels correlated with WBC counts and pus cell counts, indicating its utility in monitoring infection severity. On Day 3, an IL-6 cutoff of 2.545 pg/mL showed 77.8% sensitivity and 77 % specificity for predicting active infection (Fig 3). The percentage reduction in IL-6 levels was strongly associated with symptom improvement (Fig 4). CONCLUSION: Urinary IL-6 is a reliable biomarker for assessing UTI severity, treatment response, and infection prognosis. IL-6 levels assessed on day 3 can aid in timely de-escalation or modification of antibiotic therapy. It can complement traditional diagnostic methods and support antimicrobial stewardship practices. DISCLOSURES: All Authors: No reported disclosures